Table 2.
Characteristics of randomized patients at baselinea
| Characteristic | Usual Care (N=220) % (n) |
Intervention (N=218) % (n) |
Combined (N=438) % (n) |
|---|---|---|---|
| Age, years- median (IQR) | 54 [41, 65] | 54 [40, 63] | 54 [40, 64] |
| PDC in previous 12 months- median (IQR) | 0.86 [0.78, 0.89] | 0.88 [0.78, 0.90] | 0.87 [0.78, 0.90] |
| Sex | |||
| Female | 65.0 (143) | 71 (155) | 68 (298) |
| Male | 35.0 (77) | 29 (63) | 32 (140) |
| Race | |||
| White | 79.1 (174) | 85.3 (186) | 82.0 (360) |
| Black or African American | 15.5 (34) | 11.5 (25) | 13.5 (59) |
| Other | 1.8 (4) | 1.8 (4) | 1.8 (8) |
| Unknown | 3.6 (8) | 1.4 (3) | 2.5 (11) |
| Insurance Type | |||
| Commercial | 58.6 (129) | 57.8 (126) | 58.2 (255) |
| Medicare | 35.5 (78) | 34.4 (75) | 34.9 (153) |
| Medicaid | 5.9 (13) | 7.8 (17) | 6.8 (30) |
| Clinic Type | |||
| Adult Rheumatology | 35.5 (78) | 33.9 (74) | 34.7 (152) |
| Multiple Sclerosis | 17.7 (39) | 21.6 (47) | 19.6 (86) |
| Lipid | 17.7 (39) | 16.5 (36) | 17.1 (75) |
| Adult Miscellaneousb | 14.5 (32) | 11.5 (25) | 13 (57) |
| Pulmonaryc | 8.2 (18) | 8.7 (19) | 8.4 (37) |
| Pediatricsd | 6.4 (14) | 7.8 (17) | 7.1 (31) |
| Medication Route | |||
| Injectable | 73.6 (162) | 66 (145) | 70 (307) |
| Oral | 26.4 (58) | 34 (73) | 30 (131) |
| Active Patient Portal | |||
| Yes | 66.4 (146) | 69 (150) | 68 (296) |
| No | 33.6 (74) | 31 (68) | 32 (142) |
| Length of Therapy at Enrollment | |||
| < 1 year | 35.5 (78) | 30.7 (67) | 33.1 (145) |
| ≥1 year | 63.6 (140) | 69.3 (151) | 66.4 (291) |
| Unknown | 0.9 (2) | 0 (0) | 0.5 (2) |
PDC = Proportion of Days Covered
a
Continuous variables are presented as medians with the interquartile range in brackets. Categorical variables are presented as percentages with sample size in parentheses. Percentages may not total to 100 due to rounding.
b
Includes Adult Endocrinology, Dermatology, Hematology, Neurology and unassigned clinics
c
Includes Pediatric cystic fibrosis , Adult cystic fibrosis , Asthma, IPF and PAH
d
Includes Pediatric Irritable Bowel Disease and Pediatric Rheumatology